
    
      This is a prospective, multicentre, randomised, controlled, parallel-grouped, open-label,
      interventional clinical trial in which 1662 patients are planned to be allocated. Subjects
      will be randomized in a 1:1 ratio to receive either Albumin or routine treatment with
      crystalloids. Treatment will be continued at maximum for 28 days or until the patient leaves
      the ICU. Primary endpoint measurement will be carried out 90 days after randomisation
    
  